

Where can I read more on this subject?

If you are interested in reading more on this subject, you may of course take a look at my books. "[Herzinfarkt – Neue Wege](#)" (45) refers to all the topics included on this website and is available from Amazon for the price of 17.95€ (in German).

For those interested in "Heart Frequency Variability" ("HRV") and who would like more information on the "PNS" should read "[Herzinfarkt vermeiden](#)" (11), published by the Psychosozial Verlag. This is also available from Amazon for 19.90 € (in German).

For the curious, and especially for my sceptical medical colleagues, I have included the comprehensive overview by Giorgio Baroldi and Malcom Silver: "[The Etiopathogenesis of Coronary Heart Disease: A Heretical Theory Based on Morphology](#)" (16) as a PDF file on this website (print version). Under citation (16) a link can be found which enables you to download this file directly from the Baroldi homepage. However, it is unclear how long the Baroldi homepage will be available.

For those readers who would like to study the subject further, I have included another 3 papers on the website (print version): my publication "[On the genesis of myocardial ischemia](#)" (17), as well as two articles by H. Fürstenwerth on ouabain (90,91).

Most of the following literature can be found on "[pubmed.gov](#)". Usually, summaries of the publications are available and occasionally full text articles are free of charge.

References:

1. Rihal CS, et al.: Indications for coronary artery bypass surgery and percutaneous coronary intervention in chronic stable angina. *Circulation* (2003), 108:2439-2445
2. Murphy ML, et al.: Reatment of chronic stable angina. *N Engl J Med* (1977), 297:621-627
3. European Coronary Surgery Study Group: Long-Term Results of Prospective Randomised Study of Coronary Artery Bypass Surgery in Stable Angina Pectoris. *Lancet* (1982), ii:1173-1180
4. CASS Principle Investigators: Myocardial Infarction and Mortality in the Coronary Artery Surgery Study (CASS) Randomized Trial. *N Engl J Med* (1984), 310:750-758
5. Alderman EL, et al.: Ten-Year Follow-up of Survival and Myocardial Infarction in the Randomized Coronary Artery Surgery Study. *Circulation* (1990), 82:1629-1646
6. Takaro T, et al.: Survival in Subgroups of Patients with Left Main Coronary Artery Disease. VA Coop Study. *Circulation* (1982), 66:14-21
7. McIntosh HD, Garcia JA: The First Decade of Aortocoronary Bypass Grafting, 1967-1977. A Review. *Circulation* (1978), 57:405-431
8. Velazquez EJ, et al.: Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction. *N Engl J Med* (2011), 364:1607-1616
9. Fang JC: Underestimated Medical Therapy for Coronary Disease... Again. *N Engl J Med* (2011), 364:1671-1673
10. Block TA, et al.: Improvement in exercise performance after unsuccessful myocardial revascularization. *Am J Cardiol* (1977), 40:673-680
11. Sroka K: *Herzinfarkt vermeiden*. Psychosozial Verlag, Gießen, 2002
12. Kaunitz H: Bedeutung der Nahrungsfette bei der Arteriosklerose. *Münch Med Wschr.* (1977), 119:539

13. Kern B: Der Myokardinfarkt. Seine myokardiale Pathogenese und Prophylaxe, dargestellt am Grundriß der Linksmykardiologie. Haug, Heidelberg, 1969
14. Glatzel H: Fettverzehr und Koronarkrankheiten. *Z Allg Med* (1980), 56:445
15. Schaefer H, et al.: Herzinfarkt-Report 2000. Urban + Fischer, München, Jena, 2000
16. Baroldi G, Silver M: The Etiopathogenesis of Coronary Heart Disease: A Heretical Theory Based on Morphology. Eureka.com, Landes,Bioscience, 2004.
www.baroldi.com/public/baroldi.pdf
17. Sroka K: On the genesis of myocardial ischemia. *Z Kardiol* (2004), 93:768-783
18. Wartman WB, Hellerstein HK: The Incidence of Heart Disease in 2,000 Consecutive Autopsies. *Ann Intern Med* (1948), 28:41-65
19. Fulton WF: The Coronary Arteries: Arteriography, Microanatomy and Pathogenesis of Obliterative Coronary Artery Disease. Springfield, IL: Charles C Thomas, 1965
20. Khouri EM, et al.: Flow in the major branches of the left coronary artery during experimental coronary insufficiency in the unanesthetized dog. *Circulation Res* (1968), 23:99
21. Schaper W, Pasyk S: Influence of collateral flow on the ischemic tolerance of the heart following acute and subacute coronary occlusion. *Circulation* (1976), 53 (suppl I): I-57
22. Mills JD, et al.: Coronary collaterals development during chronic ischemia: serial assessment using harmonic myocardial contrast echocardiography. *J Am Coll Cardiol* (2000), 36:618
23. van Royen N, et al.: A Critical Review of Clinical Arteriogenesis Research. *J Am Coll Cardiol* (2010), 55:17-25
24. Doerr W, et al.: Neues und Kritisches vom und zum Herzinfarkt. Sitzungsberichte der Heidelberger Akademie der Wissenschaften. Math.-nat. Klasse. Springer, Berlin-Heidelberg-New York, 1974
25. Murakami T, et al.: Intracoronary aspiration thrombectomy for acute myocardial infarction. *Am J Cardiol* (1998), 82:839-844
26. DeWood MA, et al.: Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. *N Engl J Med* (1980), 303:897-902
27. DeWood MA, et al.: Coronary arteriographic findings soon after non-Q-wave myocardial infarction. *N Engl J Med* (1986), 315:417-423
28. Baroldi G: Significance of morphologic findings in sudden death and acute myocardial infarction. In: Schaefer H, u.a.: Herzinfarkt-Report 2000, Urban + Fischer, München, Jena, 2000
29. Ambrose JA, et al.: Angiographic progression of coronary artery disease and the development of myocardial infarction. *J Am Coll Cardiol* (1988), 12:56-62
30. Little WC, et al.: Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild to moderate coronary artery disease? *Circulation* (1988), 78:1157-1166
31. Giroud D, et al.: Relation of the site of acute myocardial infarction: implications for coronary angiography. *Clin Cardiol* (1992), 69:729-732
32. Fishbein MC, et al.: How big are coronary atherosclerotic plaques that rupture? *Circulation* (1996), 94:2662-2666
33. Airaksinen K, et al.: Impaired vagal heart control in coronary artery disease. *Br Heart J* (1987), 58:592-597
34. Kop WJ, et al: Changes in heart rate and heart rate variability before ambulatory ischemic events. *J Am Coll Cardiol* (2001), 38:742-749
35. Sroka K, et al.: Heart Rate Variability in Myocardial Ischemia During Daily Life. *J Electrocardiol* (1997), 30:45-56

36. Williamson JR, Jamieson D: Metabolic effects of epinephrine in the perfused rat heart. I. Comparison of intracellular redox states, tissue pO₂, and force of contraction. *Mol Pharmacol* (1966), 2:191-205
37. Gollwitzer-Meier K: Reaktionsänderungen im Herzen unter dem Einfluss von Adrenalin. *Pflügers Arch* (1942), 245:575-583
38. Collins-Nakai RL, et al.: Epinephrine increases ATP production in hearts by preferentially increasing glucose metabolism. *Am J Physiol* (1994), 267:H1862-H1871
39. Levy B: Lactate and shock state: the metabolic view. *Curr Opin Crit Care* (2006), 12:315-321
40. Collinson PO, et al.: Multicenter evaluation of the diagnostic value of cardiac troponin T, CK-MB mass, and myoglobin for assessing patients with suspected acute coronary syndromes in routine clinical practice. *Heart* (2003), 89:280-286
41. RITA-2 trial participants: Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. *Lancet* (1997), 350:461-468
42. RITA-3 investigators: Interventional versus conservative treatment for patients with unstable angina and non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. *Lancet* (2002), 360:743-751
43. Fox KA, et al.: 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. *Lancet* (2005), 366:914-920
44. de Winter RJ, et al.: Invasive versus Conservative Treatment in Unstable Coronary Syndromes (ICTUS) Investigators. *N Engl J Med* (2005), 353:1095-1110
45. Sroka K: Herzinfarkt – Neue Wege. BoD, Norderstedt, 2006
46. Kuklinski B: Zum Petkau-Effekt des Superoxids. Diagnostik- und Therapiezentrum für umweltmedizinische Questionn, Rostock, 2004
47. Kuklinski B: Antioxidantien in der prophylaktischen und kurativen Medizin. In: Ernährung und Immunfunktion. Herausgeber: Deutscher Kassenarztverband. Medizinische Public Relations, Gräfelfing, 1995
48. Kratz, et al.: Effects of dietary fatty acids on the composition and oxidizability of low-density lipoprotein. *Eur J Clin Nutr* (2002), 56:72-81
49. Gorbe A, et al.: Role of cGMP-PKG signaling in the protection of neonatal rat cardiac myocytes subjected to simulated ischemia/reoxygenation. *Basis Res Cardiol* (2010), 105:643-645
50. Costa AD, et al.: cGMP signaling in pre- and post-conditioning: the role of mitochondria. *Cardiovasc Res* (2008), 77:344-352
51. Garlid KD, et al.: Cardioprotective signaling to mitochondria. *J Moll Cell Cardiol* (2009), 46:858-866
52. Lei B, et al.: Exogenous nitric oxide reduces glucose transporters translocation and lactate production in ischemic myocardium in vivo. *Proc Natl Acad Sci* (2005), 102:6966-6971
53. Burley DS, et al.: Cardioprotective actions of peptide hormones in myocardial ischemia. *Heart Fail Rev* (2007), 12:279-291
54. Epstein FH: Low serum cholesterol, cancer and other noncardiovascular disorders. *Atherosclerosis* (1992), 94:1-12
55. Weverling-Rijnsburger AWE, et al.: Total cholesterol and risk of mortality in the oldest. *Lancet* (1997), 358:351-355
56. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. *Lancet* (2002), 360:7-22

57. Ignarro LJ, et al.: Nitric Oxide Donors and Cardiovascular Agents Modulating the Bioactivity of Nitric Oxide. *Circ Res* (2002), 90:21-28
58. Laufs U, et al.: Upregulation of Endothelial Nitric Oxide Synthase by HMG CoA Reductase Inhibitors. *Circulation* (1998), 97:1129-1135
59. Moschos CB, et al.: Effect of aspirin upon experimental coronary and non-coronary thrombosis and arrhythmia. *Am Heart J* (1972), 84:525-530
60. Teng CM, et al.: YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice. *Eur J Pharmacol* (1997), 320:161-166
61. Bode-Böger SM, et al.: Aspirin reduces endothelial cell senescence. *Biochem Biophys Res Commun* (2005), 334: 1226-1232
62. Grosser N, Schröder H: Aspirin protects endothelial cell from oxidant damage via the nitric oxide-cGMP pathway. *Arterioscler Thromb Vasc Biol* (2003), 23:1345-1351
63. Antiplatelet Trialist⁷ Collaboration: Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. *Br Med J* (1994), 308:81-106
64. Rozanski A, et al.: Impact of Psychological Factors on the Pathogenesis of Cardiovascular Disease and Implications for Therapy. *Circulation* (1999), 99:2192-2217
65. Frasure-Smith N, et al.: The Ischemic Heart Disease Life Stress Monitoring Program: Impact on Mortality: *Psychosom Med* (1985), 47:431-445
66. Harrison LL, et al.: Effects of early parent touch on preterm infants' heart rates and arterial oxygen saturation levels. *J Adv Nurs* (1990), 15:877-885
67. McCraty R, et al.: The Effects of Emotions on Short-Term Power Spectrum Analysis of Heart Rate Variability. *Am J Cardiol* (1995), 76:1089-1093
68. Dohrmann RE, Dohrmann M: Neuere Therapie der instabilen Angina pectoris bei koronarer Herzerkrankung. *Erfahrungsheilkunde – acta medica empirica* (1984), 33:183-190
69. Salz H, Schneider B: Perlinguales g-Strophanthin bei stabiler Angina pectoris. *Z f Allgemeinmedizin* (1985), 61:1223-1228
70. Sarre H: Strophanthinbehandlung bei Angina pectoris. *Therapiewoche* (1952/53), 3:311-314
71. Brembach H: Infarktvorbeugung in der Arbeitsmedizin. *Notabene medici* (1984), 7:613-616
72. Dohrmann RE, et al.: Klinisch-poliklinische Studie über die Wirksamkeit von g-Strophanthin bei Angina pectoris und Myokardinfarkt. *Cardiol Bull* (1977), 14/15:183-187
73. Agostini PG, et al.: Long-Term Use of K-Strophanthin in Advanced Congestive Heart Failure Due to Dilated Cardiomyopathy: A Double-Blind Crossover Evaluation Versus Digoxin. *Clin Cardiol* (1994), 17:536-541
74. Löhr E, et al.: Beitrag zur Membranpermeabilität von Cardiaca (g-Strophanthin, Digoxin und Oxyfedrin) aufgrund von Mikro-Autoradiographien am Meerschweinchenherzen. *Arzneimittelforschung* (1971), 21:921-927
75. Weitkamp, et al. (2003): <http://www.vetmed.uni-giessen.de/biochem/schoner/Abschiedsvorlesung.html>, p.26
76. Oselkin M, et al.: Low dose cardiotoxic steroids increase sodium-potassium ATPase activity that protects hippocampal slice cultures from experimental ischemia. *Neurosci Lett* (2010), 473:67-71
77. DeMots H, et al.: Effects of Ouabain on Myocardial Oxygen Supply and Demand in Patients with Chronic Coronary Artery Disease. *J Clin Invest* (1976), 58:312-319

78. Gremels H: Über den Einfluß von Digitalisglykosiden auf die energetischen Vorgänge am Säugetierherzen. *Arch Exp Path Pharmacol* (1937), 186:625-660
79. Gillis RA, Quest JA: The Role of the Nervous System in the Cardiovascular Effects of Digitalis. *Pharmacol Rev* (1979), 31:19-97
80. Slatton ML, et al.: Does digoxin provide additional hemodynamic and autonomic benefit at higher doses in patients with mild to moderate heart failure and normal sinus rhythm? *J Am Coll Cardiol* (1997), 29:1206-1213
81. Paton WDM, et al.: The mechanism of acetylcholine release from parasympathetic nerves. *J Physiol* (1971), 215:819-848
82. Satoh E, Nakazato Y: On the Mechanism of Ouabain-Induced Release of Acetylcholine from Synaptosomes. *J Neurochem* (1992), 58:1038-1044
83. Kull J: Strophanthinwirkung und cholinergischer Mechanismus am Herz. *Arch Exp Path Pharmacol* (1939), 192:447-456
84. Pierre SV, et al.: Ouabain triggers preconditioning through activation of the Na⁺,K⁺-ATPase signaling cascade in rat hearts. *Cardiovasc Res* (2007), 73:488-496
85. Pasdois PP, et al: Ouabain protects rat hearts against ischemia-reperfusion injury via a pathway involving src kinase, mitoK_{ATP}, and ROS. *Am J Physiol* (2007), 292:H1470-H1478
86. Shah Y: Strophanthin – ein besonderes Herzglykosid. *Z f Komplementärmedizin* (2011), 2:48-51
87. Shah Y: Heilpflanzenporträt: Strophanthus. *ZKM* (2011), 2:58
88. Hamlyn J, et al: Welcome to ouabain – a new steroid hormone. Editorial, *Lancet* (1991), 338:543-544
89. Petry RJ: Die Lösung des Herzinfarkt-Problems durch Strophanthin. Frolegium Verlag, Bremen, 2006
90. Fürstenwerth H: Ouabain – the insulin of the heart. *Clin Pract* (2010), 64:1591-1594
91. Fürstenwerth H: On the differences between ouabain and digitalis glycosides. *Am J Therap* (2011)
92. Ruiz G, et al.: Homeopathic effect on heart rate variability. *Br Homeopath J* (1999), 88:106-111
93. Huang J, et al.: Heart rate variability depression in patients with unstable angina. *Am Heart J* (1995), 130:772-779
94. Liao D, et al.: Cardiac Autonomic Function and Incident Coronary heart Disease: A Population-based Case-Cohort Study. The ARIC Study. *Am J Epidemiol* (1997), 145:696-706
95. Tsuji H, et al.: Impact of Reduced Heart Rate Variability on Risk for Cardiac Events. *Circulation* (1996), 94:2850-2855